Principal Financial Group Inc Arcellx, Inc. Transaction History

Principal Financial Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$50.91 - $86.61 $1.7 Million - $2.89 Million	-33,334 Reduced 89.24%	4,018 $335,000
Q2 2024 Jul 29, 2024	BUY	$49.74 - $66.98 $25,715 - $34,628	517 Added 1.4%	37,352 $2.06 Million
Q1 2024 Apr 29, 2024	BUY	$51.85 - $73.49 $1.36 Million - $1.93 Million	26,197 Added 246.26%	36,835 $2.56 Million
Q4 2023 Feb 07, 2024	BUY	$31.75 - $57.99 $4,349 - $7,944	137 Added 1.3%	10,638 $590,000
Q3 2023 Nov 02, 2023	SELL	$31.51 - $37.4 $8,507 - $10,098	-270 Reduced 2.51%	10,501 $376,000
Q2 2023 Aug 07, 2023	BUY	$27.49 - $46.9 $23,009 - $39,255	837 Added 8.43%	10,771 $340,000
Q1 2023 May 09, 2023	BUY	$26.92 - $33.94 $27,808 - $35,060	1,033 Added 11.61%	9,934 $306,000
Q4 2022 Feb 09, 2023	BUY	$17.18 - $33.0 $152,919 - $293,733	8,901 New	8,901 $275,000

205

44.1M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.94B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.